nCounter® miRNA Expression Assays


Discover biomarkers with highly multiplexed, direct digital detection and quantification of miRNAs in a single reaction. nCounter® miRNA assays include panels for miRNA expression analysis and simultaneous measurement of miRNA and mRNA from the same sample. The content is curated from latest miRBase to enable you to rapidly and efficiently profile the top 800 human miRNA’s. Also available for rat and mouse species.

"nCounter® microRNA panels have allowed us to comprehensively screen human and rat tissue for microRNA profiles in our disease setting of interest. This has allowed us to select candidate microRNA signatures of interest for expanded validation and further interrogation."

-Rachel Crossland, Ph.D., Newcastle University

Researchers have demonstrated the value of nCounter® miRNA Assays in numerous publications with data across a variety of sample types and in a wide range of biological applications. nCounter® miRNA Expression Assays have been used to profile miRNAs from a variety of sample types, in a wide range of biological areas of research, including cell signaling and cancer biology, neuroscience, stem cell research, autophagy, infectious disease, and immunology.

Download the Tech Note on miRNA detection in serum and the White Paper on miRNA applications today!

miRNA Assay Sample Preparation
miRNA Assay Protocol
microRNAs as bile-based biomarkers
Profiling miRNA Biomarkers in Cells, FFPE, and Clinical Biofluid Samples

NanoString’s FFPE-compatible chemistry allows for tens of thousands of data points to be generated per day in FFPE sample types that are important in translational research.

Christmann R. et al. (2016) performed biomarker analysis on tissue samples from patients with SSc-ILD to find miR-155 in the progression of lung fibrosis in systemic sclerosis using the nCounter® Human (V2) miRNA Expression Assay CodeSet.

Luciano C. et al. (2013) found interesting integrated miRNA and mRNA signatures associated with survival in triple-negative breast cancer using the nCounter® miRGE™ Assay (simultaneous analysis of miRNA and mRNA in the same sample).

The discovery of relatively stable, extracellular miRNAs in serum and plasma has generated huge interest as non-invasive biomarkers for a variety of diseases.

Permuth-Wey J. et al. (2015) discovered novel miRNA biomarkers in plasma samples for patients with intraductal papillary mucinous neoplasms of the pancreas using the nCounter® Human v3 miRNA Expression Assay .

Stylli S.S. et al. (2016) profiled miRNA in cerebrospinal fluid in patients with aneurysmal subarachnoid hemorrhage using the nCounter® Human v3 miRNA Expression Panel.

NanoString profiling using nCounter® Human v3 miRNA Expression Panel indicates differential serum expression levels of circulating miRNAs in healthy controls and children with mild or severe symptoms of EV71. Read more in Elevated expression of circulating miR876-5p is a specific response to severe EV71 infections by Wang R. et al. (2016).

Exosomal miRNAs play an important role in disease progression and can stimulate angiogenesis and facilitate metastasis in cancers 1.


Topol A. et al. (2016) used the nCounter® Human v3 miRNA Expression Assay to study dysregulation of miRNA-9 in a subset of schizophrenia patent-derived neural progenitor cells.

Rodosthenis S. et al. (2016) performed a pilot study of older individuals by studying ambient particulate matter and miRNA in extracellular vesicles using nCounter® Human (V2) miRNA Expression Assay CodeSet.


miRNAs have been identified as potential cancer biomarkers due to their presence and stability in many body fluids including urine.

Armstrong D.A. et al. (2015) profiled miRNA from matched tumor and biofluids in bladder cancer using the nCounter® Human v3 miRNA Expression Assay.

Click here to view applications regarding nCounter® Expression Assays.

Contact Us Watch our webinar today

For Research Use Only. Not for use in diagnostic procedures.